Drugs / UCB-NK cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04347616 | Dec 2020 → Jan 2026 | acute myeloid leukemia | Radboud University Medical Center | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCB-NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04347616 ↗ |
| Modality | Cell therapy | “This study investigates an innovative treatment for relapsed or refractory acute myeloid leukemia exploiting administration of ex vivo-generated allogeneic natural killer (NK) cells” NCT04347616 ↗ |